TIGRa: A Smaller Gene Activation Platform for In Vivo Delivery
Stanford Medicine researchers have developed a compact gene activation platform named TIGRa, which is less than half the size of conventional CRISPR-based activators and capable of in vivo delivery via adeno-associated viruses, according to a proof-of-concept study led by Yang Sun. Understanding the TIGRa Gene Activation Platform The CRISPR-Cas9 system revolutionized genome editing and targeted … Read more